Geneos Wealth Management Inc. Has $993,000 Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Geneos Wealth Management Inc. grew its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,309 shares of the company’s stock after buying an additional 73 shares during the quarter. Geneos Wealth Management Inc.’s holdings in HCA Healthcare were worth $993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new position in shares of HCA Healthcare during the 3rd quarter valued at $39,000. Capital Performance Advisors LLP acquired a new stake in shares of HCA Healthcare in the third quarter worth about $41,000. Canoe Financial LP bought a new position in shares of HCA Healthcare in the 3rd quarter valued at approximately $41,000. Northwest Investment Counselors LLC bought a new stake in HCA Healthcare during the third quarter worth approximately $44,000. Finally, Friedenthal Financial acquired a new stake in shares of HCA Healthcare in the third quarter worth $50,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Buying and Selling at HCA Healthcare

In related news, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the transaction, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $332.18 on Tuesday. The stock has a fifty day moving average price of $313.49 and a two-hundred day moving average price of $353.13. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare, Inc. has a 52-week low of $281.61 and a 52-week high of $417.14. The firm has a market capitalization of $84.14 billion, a P/E ratio of 14.92, a P/E/G ratio of 1.09 and a beta of 1.64.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.52% and a return on equity of 520.98%. During the same quarter in the previous year, the business earned $5.90 EPS. As a group, analysts anticipate that HCA Healthcare, Inc. will post 21.75 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 17th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.87%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date of this dividend is Monday, March 17th. HCA Healthcare’s payout ratio is currently 11.85%.

Analysts Set New Price Targets

HCA has been the subject of a number of research analyst reports. Wells Fargo & Company lowered shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $400.00 to $320.00 in a research report on Monday, November 25th. Truist Financial decreased their target price on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Raymond James lowered HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. StockNews.com cut shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Royal Bank of Canada dropped their price objective on shares of HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a report on Monday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $382.19.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.